Regnology Announces 32nd Annual RegTech Convention on 17-20 November
25.9.2025 16:00:00 EEST | Business Wire | Press release
Regnology, a global leading software provider of regulatory reporting and supervisory technology solutions, is proud to announce the 32nd Annual RegTech Convention, set to take place from November 17–19, 2025 in Frankfurt, Germany and in Zürich, Switzerland on November 20. The hybrid event will convene more than 2,000 participants from over 120 countries for four days of knowledge sharing and keynotes across 40+ sessions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250925695598/en/
This year’s theme, “Straight-Through-Reporting (STR): Entering a New Era of Regulatory Intelligence” will examine how STR – which draws inspiration from Straight-Through Processing (STP) in capital markets – can transform regulatory operations into a more data-driven, seamless and collaborative framework. Discussions will span timely topics such as crypto reporting, AI, granular data, Basel IV (CRR3), CARF/DAC8 — with dedicated SupTech, RegTech, and Tax programs.
Headlining the agenda are keynotes from Tomas Sedlacek, international economy expert and author, who will open with a perspective on the state of financial regulatory reporting—examining geopolitical dynamics and systemic pressures. Jan Hendrik Schmidt, senior adviser and head of the Artificial Intelligence Hub at the ECB’s Horizontal Supervision Directorate, will share insights on the evolution of data from a compliance byproduct to strategic infrastructure.
The conference will also feature a distinguished lineup of 60+ speakers from major financial authorities, supervisory bodies, financial and technology firms, including senior representatives from the ECB, Oesterreichische Nationalbank (OeNB), European Insurance and Occupational Pensions Authority (EIOPA), the Central Bank of Ireland, Commerzbank, FlatexDEGIRO, and Firebrand Research— with many more to be announced.
As in previous years, the convention offers a global platform for exchange between regulators and the regulated community. This year, it expands with 2 new regional editions in New York and Singapore, in addition to local community events across London, Paris, Warsaw, Geneva, Zurich and Bellinzona.
Rob Mackay, CEO of Regnology, said: “Straight-Through-Reporting (STR) has the potential to be as transformative for regulation as STP was for capital market. This convention will unite financial regulators, supervisors, and financial institutions to chart the course toward more connected, streamlined and resilient reporting frameworks — unlocking a new era of regulatory intelligence.”
The RegTech Convention is free to attend for regulatory authorities and financial institutions, with both in-person and virtual attendance options. The full event will be live-streamed and accessible on-demand following the convention.
To view the full agenda and register, please visit: https://www.regtech-convention.com/en/register/?utm_campaign=2025_RegTech%20Convention&utm_medium=referral&utm_source=pr
About Regnology
Regnology is a leading technology firm on a mission to enhance efficiency, transparency, and stability in the financial markets. Regnology has a focus on regulatory reporting with thousands of financial institutions and corporates of all sizes, and close to 100 regulators and tax authorities as clients. Regnology connects regulators and regulated financial institutions across the world through purpose-built solutions and common standards, bringing greater data quality and cost savings to all. With over 1,200 employees in 25 countries and a fast, flexible, and future-proof platform, clients can quickly implement and derive value from Regnology’s solutions and rely on us to easily keep pace with ongoing regulatory changes. Regnology was formed in 2021 when BearingPoint RegTech, a former business unit of BearingPoint Group, joined forces with Vizor Software, a global leader in regulatory and supervisory technology.
For more information about Regnology, connect with us on LinkedIn and X.
Visit our website: www.regnology.net.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250925695598/en/
Contacts
Press Contact
Mireille Adebiyi – Chief Marketing Officer, Regnology
mireille.adebiyi@regnology.net
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom